<DOC>
	<DOCNO>NCT02568046</DOCNO>
	<brief_summary>This phase 1b/2a study investigate safety effect Sym004 combination FOLFIRI ( chemotherapy ) administer every second week . The phase 1b ( dose-escalation ) portion trial expect begin Q1 2016 . Patients sequentially enrol dose-escalation cohort establishment Maximum Tolerated Dose ( MTD ) Recommended Phase 2 Dose ( RP2D ) Sym004 combination FOLFIRI . The phase 2a ( dose-expansion ) portion trial expect begin establish RP2D .</brief_summary>
	<brief_title>Sym004 Combination With FOLFIRI Metastatic Colorectal Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Main inclusion Criteria : 1 . Male female , least 18 year age time inform consent 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 3 . Histologically cytologically confirm , locally advanced metastatic colorectal cancer ( CRC ) document without Kirsten rat sarcoma ( KRAS ) Neuroblastoma rat sarcoma ( NRAS ) gene mutation ( i.e . tumor must express KRAS NRAS wild type ( WT ) , exon 2 , 3 4 ) . 4 . Failed* treatment locally advance metastatic disease firstline combination therapy oxaliplatin fluoropyrimidine , without bevacizumab , treatment &lt; 3 month last dose firstline therapy within &lt; 3 month C1/D1 . Patients discontinued firstline therapy due toxicity may enrol provided progression occur &lt; 6 month last dose firstline therapy regimen . Failed* adjuvant therapy combination therapy oxaliplatin fluoropyrimidine treatment within &lt; 6 month last dose oxaliplatin within &lt; 6 month C1/D1 . Failure define radiologic progression 5 . Eligible FOLFIRI 6 . Measurable disease accord RECIST v1.1 Main exclusion Criteria : 1 . Prior therapy antiEGFR antibody , antiEGFR small molecule inhibitor irinotecan ( CPT11 ) 2 . Any antineoplastic agent ( standard investigational ) within 4 week prior C1/D1 3 . Significant gastrointestinal abnormality 4 . Patients significant cardiovascular disease condition 5 . Abnormal hematologic , renal hepatic function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
</DOC>